Last €78.09 EUR
Change Today -0.323 / -0.41%
Volume 2.8K
JNJ On Other Exchanges
Symbol
Exchange
Xetra
Mexico
Sao Paulo
Bogota
As of 11:35 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Open
€78.46
Previous Close
€78.41
Day High
€78.80
Day Low
€78.08
52 Week High
08/27/14 - €78.80
52 Week Low
10/9/13 - €63.00
Market Cap
220.2B
Average Volume 10 Days
3.2K
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
08/22/14
P/E TM
--
Dividend
€2.79
Dividend Yield
2.57%
Current Stock Chart for JOHNSON & JOHNSON (JNJ)

johnson & johnson (JNJ) Details

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

Founded in 1885

johnson & johnson (JNJ) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $842.3K
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $2.7M
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $952.9K
Vice President, General Counsel and Member of...
Total Annual Compensation: $542.3K
Compensation as of Fiscal Year 2013.

johnson & johnson (JNJ) Key Developments

Nobel Biocare Said To Draw Interests

Nobel Biocare Holding AG (SWX:NOBN) ) that’s exploring a sale, has attracted interest from potential buyers including EQT Partners AB and Danaher Corp. (NYSE:DHR), said people with knowledge of the matter. Nobel Biocare was initially approached by EQT with an offer of about CHF 17 a share, which would have valued the company at about CHF 2.1 billion said the people, who asked not to be identified because talks are private. The offer prompted Nobel Biocare and its adviser Goldman Sachs Group Inc. (GS) to invite other bids as it seeks a higher price, the people said. Other companies such as DENTSPLY International Inc. (NasdaqGS:XRAY) and buyout firms are also expected to look at Nobel Biocare, the people said. Potential buyers include Straumann Holding AG (SWX:STMN), Sirona Dental Systems Inc., Johnson & Johnson (NYSE:JNJ), Medtronic, Inc. (NYSE:MDT), Zimmer Holdings, Inc. (NYSE:ZMH), Henry Schein, Inc. (NasdaqGS:HSIC), and 3M Company (NYSE:MMM), according to a note on July 30 from Lisa Bedell Clive, a London-based analyst at Sanford C. Bernstein & Co. Nobel Biocare could sell for as much as CHF 18 a share, she said in the note.

Johnson & Johnson Announces Dividend for the Third Quarter of 2014, Payable on September 9, 2014

NEW Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the third quarter of 2014 of $0.70 per share on the company's common stock. The dividend is payable on September 9, 2014 to shareholders of record at the close of business on August 26, 2014. The ex-dividend date is August 22, 2014.

Johnson & Johnson Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months of 2014; Provides Earnings Guidance for the Full Year of 2014

Johnson & Johnson announced unaudited consolidated earnings results for the second quarter and six months of 2014. For the quarter, the company reported sales to customers of $19,495 million against $17,877 million a year ago. Earnings before provision for taxes on income were $5,626 million against $4,793 million a year ago. Net earnings were $4,326 million against $3,833 million a year ago. Diluted net earnings per share were $1.51 against $1.33 a year ago. Adjusted earnings before provision for taxes on income were $6,050 million against $5,359 million a year ago. Adjusted net earnings were $4,775 million against $4,289 million a year ago. Adjusted diluted net earnings per share were $1.66 against $1.48 a year ago. For the six months, the company reported sales to customers of $37,610 million against $35,382 million a year ago. Earnings before provision for taxes on income were $11,050 million against $9,054 million a year ago. Net earnings were $9,053 million against $7,330 million a year ago. Diluted net earnings per share were $3.15 against $2.55 a year ago. Adjusted earnings before provision for taxes on income were $11,610 million against $10,429 million a year ago. Adjusted net earnings were $9,201 million against $8,396 million a year ago. Adjusted diluted net earnings per share were $3.20 against $2.92 a year ago. The company increased its earnings guidance for full-year of 2014 to $5.85 to $5.92 per share. The company's guidance excludes the impact of special items.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:GR €78.09 EUR -0.323

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JNJ.
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
No financial data is available for JNJ.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.